The publication of this infographic was sponsored by Menarini Stemline and is based on a symposium presented at the European Society for Medical Oncology (ESMO) Congress 2024.
This infographic, the first in a three-part series, explores the development of resistance to endocrine therapy in ER+/HER2- advanced breast cancer. Covering the unmet needs in second-line treatment for these patients, this infographic describes the limitations in progression-free survival, and the toxicity associated with many potential combination therapies.
